Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
Business Group on Health found that 87% of employers expected oral GLP-1s to increase demand, while only 9% expected prices to fall
In 2025, nearly three-quarters (72%) face an out-of-pocket maximum of more than $3,000 for single coverage, including one in five (21%) who face an out-of-pocket maximum of more than $6,000
Melanin: the biophysiology of oral melanocytes and physiological oral pigmentation
Garetosmab, activin A inhibitor antibody for muscle-preservation combination regimens in obesity Recent Highlights: In June 2026, the company announced it would present new clinical data from the Phase 2 COURAGE trial that examines the effects of trevogrumab (anti-GDF8) on lean mass in people with obesity treated with semaglutide
Hernandez AF, Green JB, Janmohamed S, DAgostino RB, Sr., Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S
US$ 29.51
US$ 28.70
US$ 24.06
US$ 28.52
